Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Ezetimibe Added to Ongoing Statin Therapy on C-Reactive Protein Levels in Hypercholesterolemic Patients

  • Oh, Min-Seok (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Min, Yun-Joo (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Kwon, Jee-Eun (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Cho, Eun-Jeong (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Kim, Jung-Eun (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Lee, Wang-Soo (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Lee, Kwang-Je (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Kim, Sang-Wook (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Kim, Tae-Ho (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Kim, Chee-Jeong (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University) ;
  • Ryu, Wang-Seong (Division of Cardiology, Department of Internal Medicine, College of Medicine, Chung-Ang University)
  • Published : 2011.05.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Ezetimibe alone does not decrease C-reactive protein (CRP) levels in hypercholesterolemic patients. However, several reports have suggested that ezetimibe might potentiate the effect of statin not only on cholesterol but also on CRP when administered together. We investigated the effect of ezetimibe on CRP levels in patients taking statins. Subjects and Methods: Patients who had not achieved recommended low density lipoprotein-cholesterol (LDL-C) goals with statin therapy were divided into two groups, the ezetimibe group (n=60) and the control group (n=60). A third group of hypercholesterolemic patients without statin therapy was treated with statin (n=59). Patients with CRP level 10 mg/L were excluded. Lipid and CRP levels were measured before therapy commenced, and after 2 months of therapy. Results: Ezetimibe decreased cholesterol and LDL-C levels by 20.2% (p=0.000) and 28.1% (p=0.000) respectively. However, ezetimibe did not reduce CRP levels (from 0.83${\pm}$0.68 to 1.14${\pm}$1.21 mg/dL, p=0.11). CRP levels remained unchanged in the control group (p= 0.42). In contrast, statin lowered CRP levels (from 0.82${\pm}$0.73 to 0.65${\pm}$0.57 mg/dL, p=0.008). In patients taking statins, changes in CRP levels were not associated with changes in LDL-C (r=-0.02, p=0.87), but with baseline CRP levels (r=-0.38, p=0.000). Conclusion: Ezetimibe failed to reduce CRP levels in hypercholesterolemic patients taking statins despite significant reduction of LDL-C. This finding suggests that the anti-inflammatory effect of statin may not be secondary to cholesterol reduction, but via other mechanisms.

Keywords

References

  1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. https://doi.org/10.1016/S0140-6736(05)67394-1
  2. Kim CJ. In the shadow of the "Statin Festival". Korean Circ J 2006; 36:77-83.
  3. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007;99:732-8. https://doi.org/10.1016/j.amjcard.2006.09.125
  4. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109 (Suppl 1):III39-43.
  5. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-8. https://doi.org/10.1210/jc.87.4.1451
  6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26. https://doi.org/10.1056/NEJM199901143400207
  7. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72. https://doi.org/10.1161/01.CIR.104.3.365
  8. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-47. https://doi.org/10.1093/oxfordjournals.aje.a008963
  9. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. https://doi.org/10.1161/01.CIR.0000053730.47739.3C
  10. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circula-tion 1999;100:230-5. https://doi.org/10.1161/01.CIR.100.3.230
  11. Jung KS, Lee KE, Lee SH, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor on high sensitivity C-reactive protein le-vels in hypercholesterolemic patients without atherosclerotic diseases. Korean Circ J 2004;34:381-7.
  12. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in pa-tients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7. https://doi.org/10.1016/S0002-9149(02)02798-4
  13. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new chole-sterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41.
  14. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe co-administered with atorvastatin in 628 patients with primary hypercho-lesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15. https://doi.org/10.1161/01.CIR.0000068312.21969.C8
  15. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of eze-timibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-8. https://doi.org/10.1016/j.amjcard.2003.08.048
  16. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91. https://doi.org/10.1016/S0002-9149(02)02774-1
  17. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007;49:1035-42. https://doi.org/10.1016/j.jacc.2006.10.064
  18. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ez-etimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356-63. https://doi.org/10.1161/01.CIR.0000164260.82417.3F
  19. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006;27:1182-90.
  20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. https://doi.org/10.1001/jama.285.19.2486
  21. Kim CJ. Effects of fenofibrate on C-reactive protein levels in hypertri-glyceridemic patients. J Cardiovasc Pharmacol 2006;47:758-63. https://doi.org/10.1097/01.fjc.0000211787.30034.0a
  22. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-73. https://doi.org/10.1016/j.ahj.2004.11.023
  23. Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-bl-ind, placebo-controlled, factorial design study to evaluate the lipid-al-tering efficacy and safety profile of the ezetimibe/simvastatin tablet com-pared with ezetimibe and simvastatin monotherapy in patients with pri-mary hypercholesterolemia. Clin Ther 2004;26:1758-73. https://doi.org/10.1016/j.clinthera.2004.11.016
  24. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccuttin D. Com-parison of effects of ezetimibe/simvastatin versus simvastatin versus at-orvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007;99:1706-13. https://doi.org/10.1016/j.amjcard.2007.01.062
  25. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Pal-misano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hy-percholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-95. https://doi.org/10.4065/80.5.587
  26. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207. https://doi.org/10.1056/NEJMoa0807646
  27. Pearson TA, Denke MA, McBride PE, et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 2006;81:1177-85. https://doi.org/10.4065/81.9.1177
  28. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 2009;103:369-74. https://doi.org/10.1016/j.amjcard.2008.09.090
  29. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-as-sociated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009;119:131-8. https://doi.org/10.1161/CIRCULATIONAHA.108.813311
  30. Conard SE, Bays HE, Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008;102:1489-94. https://doi.org/10.1016/j.amjcard.2008.09.075